Company News: Pfizer

Share this article:
Pfizer said last night that it suspended the osteoarthritis clinical program for investigational compound tanezumab following a certain number of reports that tanezumab patients had their osteoarthritis worsen leading to joint replacement. The product was being studied as a way to treat pain associated with the condition. Pfizer said the adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. Pfizer said the monoclonal antibody is still being studied in conditions such as cancer pain, low back pain and pain associated with diabetes.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions